Iovance Biotherapeutics Inc Total Liabilities
Iovance Biotherapeutics Inc total liabilities. Based on the latest financial reports, Iovance Biotherapeutics Inc (IOVA) has total liabilities worth $202.66 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Iovance Biotherapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Iovance Biotherapeutics Inc (2008–2024)
Total liabilities of Iovance Biotherapeutics Inc from 2008 to 2024. This chart illustrates how Iovance Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Iovance Biotherapeutics Inc to see how much of total assets are deployed in long-term investments.
Iovance Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Iovance Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WEIBO CORP. A
F:2WB
|
Germany | €3.08 Billion |
|
Hbt Financial Inc
NASDAQ:HBT
|
USA | $6.03 Billion |
|
Ningbo Kangqiang Electronics Co Ltd
SHE:002119
|
China | CN¥1.58 Billion |
|
E2open Parent Holdings Inc
NYSE:ETWO
|
USA | $1.48 Billion |
|
Abacus Storage King
AU:ASK
|
Australia | AU$1.36 Billion |
|
alstria office REIT-AG
XETRA:AOX
|
Germany | €2.93 Billion |
|
Hotel101 Global Holdings Corp. Class A Ordinary Shares
NASDAQ:HBNB
|
USA | $135.19 Million |
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
Indonesia | Rp6.08 Trillion |
Liability Composition Analysis (2008–2024)
This chart breaks down Iovance Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Iovance Biotherapeutics Inc.
Liquidity & Leverage Metrics
Iovance Biotherapeutics Inc Total Liabilities Ratios Explained
Iovance Biotherapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Iovance Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Iovance Biotherapeutics Inc (2008–2024)
The table below shows the annual total liabilities of Iovance Biotherapeutics Inc from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $200.02 Million | +2.19% |
| 2023-12-31 | $195.74 Million | +19.10% |
| 2022-12-31 | $164.34 Million | +5.57% |
| 2021-12-31 | $155.67 Million | +39.04% |
| 2020-12-31 | $111.96 Million | +145.07% |
| 2019-12-31 | $45.68 Million | +212.31% |
| 2018-12-31 | $14.63 Million | +47.88% |
| 2017-12-31 | $9.89 Million | +99.11% |
| 2016-12-31 | $4.97 Million | +204.79% |
| 2015-12-31 | $1.63 Million | -1.91% |
| 2014-12-31 | $1.66 Million | -26.79% |
| 2013-12-31 | $2.27 Million | -80.00% |
| 2012-12-31 | $11.35 Million | -14.99% |
| 2011-12-31 | $13.35 Million | +1522.30% |
| 2010-12-31 | $822.87K | +3459.11% |
| 2009-12-31 | $23.12K | +594.71% |
| 2008-12-31 | $3.33K | -- |
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic me… Read more